Advertisement
Screener

BLACK DIAMOND THERAPEUTICS, INC. (BDTX) Increase (Decrease) in Accounts Payable, Trade

BLACK DIAMOND THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable, Trade

BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Increase (Decrease) in Accounts Payable, Trade of $825.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsPayableTrade · last filed 2026-08-05

  • BLACK DIAMOND THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for the quarter ending 2026-06-30 was -$1.56M.
  • BLACK DIAMOND THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for the quarter ending 2026-03-31 was $2.39M.
  • BLACK DIAMOND THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for the quarter ending 2025-12-31 was -$396.00K, a 119.45% decline year-over-year.
  • BLACK DIAMOND THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for the quarter ending 2025-09-30 was $204.00K, a 83.11% decline year-over-year.
  • BLACK DIAMOND THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for fiscal 2025 was -$3.43M, a 303.68% decline from fiscal 2024.
  • BLACK DIAMOND THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for fiscal 2024 was $1.68M, a 181.91% increase from fiscal 2023.
  • BLACK DIAMOND THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for fiscal 2023 was $597.00K.
  • BLACK DIAMOND THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for fiscal 2022 was -$2.23M, a 242.13% decline from fiscal 2021.
Period endIncrease (Decrease) in Accounts Payable, Trade 3 monthIncrease (Decrease) in Accounts Payable, Trade 6 monthIncrease (Decrease) in Accounts Payable, Trade 9 monthIncrease (Decrease) in Accounts Payable, Trade 12 month
2026-06-30-$1.56M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$825.00K
10-Q · filed 2026-08-05
$429.00K
derived: sum of 3 quarters · filed 2026-08-05
$633.00K
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31$2.39M
10-Q · filed 2026-05-07
$1.99M
derived: sum of 2 quarters · filed 2026-05-07
$2.20M
derived: sum of 3 quarters · filed 2026-05-07
$341.00K
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31-$396.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16
-$192.00K
derived: sum of 2 quarters · filed 2026-03-16
-$2.05M
derived: sum of 3 quarters · filed 2026-08-05
-$3.43M
10-K · filed 2026-03-16
2025-09-30$204.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$1.65M
derived: sum of 2 quarters · filed 2026-08-05
-$3.03M
10-Q · filed 2025-11-06
-$996.00K
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30-$1.86M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
-$3.24M
10-Q · filed 2026-08-05
-$1.20M
derived: sum of 3 quarters · filed 2026-08-05
$8.00K
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31-$1.38M
10-Q · filed 2026-05-07
$657.00K
derived: sum of 2 quarters · filed 2026-05-07
$1.86M
derived: sum of 3 quarters · filed 2026-05-07
$1.43M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$2.04M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16
$3.24M
derived: sum of 2 quarters · filed 2026-03-16
$2.81M
derived: sum of 3 quarters · filed 2026-03-16
$1.68M
10-K · filed 2026-03-16
2024-09-30$1.21M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$775.00K
derived: sum of 2 quarters · filed 2025-11-06
-$353.00K
10-Q · filed 2025-11-06
$1.28M
derived: sum of 4 quarters · filed 2025-11-06
2024-06-30-$433.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
-$1.56M
10-Q · filed 2025-08-07
$69.00K
derived: sum of 3 quarters · filed 2025-08-07
-$1.79M
derived: sum of 4 quarters · filed 2025-08-07
2024-03-31-$1.13M
10-Q · filed 2025-05-12
$502.00K
derived: sum of 2 quarters · filed 2025-05-12
-$1.36M
derived: sum of 3 quarters · filed 2025-05-12
-$1.70M
derived: sum of 4 quarters · filed 2025-05-12
2023-12-31$1.63M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06
-$229.00K
derived: sum of 2 quarters · filed 2025-03-06
-$572.00K
derived: sum of 3 quarters · filed 2025-03-06
$597.00K
10-K · filed 2025-03-06
2023-09-30-$1.86M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05
-$2.20M
derived: sum of 2 quarters · filed 2024-11-05
-$1.03M
10-Q · filed 2024-11-05
-$4.92M
derived: sum of 4 quarters · filed 2024-11-05
2023-06-30-$343.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06
$826.00K
10-Q · filed 2024-08-06
-$3.06M
derived: sum of 3 quarters · filed 2024-08-06
$481.00K
derived: sum of 4 quarters · filed 2024-08-06
2023-03-31$1.17M
10-Q · filed 2024-05-09
-$2.71M
derived: sum of 2 quarters · filed 2024-05-09
$824.00K
derived: sum of 3 quarters · filed 2024-05-09
$1.16M
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31-$3.88M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12
-$345.00K
derived: sum of 2 quarters · filed 2024-03-12
-$6.00K
derived: sum of 3 quarters · filed 2024-03-12
-$2.23M
10-K · filed 2024-03-12
2022-09-30$3.54M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06
$3.88M
derived: sum of 2 quarters · filed 2023-11-06
$1.65M
10-Q · filed 2023-11-06
$959.00K
derived: sum of 4 quarters · filed 2023-11-06
2022-06-30$339.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11
-$1.89M
10-Q · filed 2023-08-11
-$2.58M
derived: sum of 3 quarters · filed 2023-08-11
-$1.95M
derived: sum of 4 quarters · filed 2023-08-11
2022-03-31-$2.22M
10-Q · filed 2023-05-09
-$2.92M
derived: sum of 2 quarters · filed 2023-05-09
-$2.29M
derived: sum of 3 quarters · filed 2023-05-09
-$2.65M
derived: sum of 4 quarters · filed 2023-05-09
2021-12-31-$694.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09
-$66.00K
derived: sum of 2 quarters · filed 2023-03-09
-$422.00K
derived: sum of 3 quarters · filed 2023-03-09
$1.57M
10-K · filed 2023-03-09
2021-09-30$628.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08
$272.00K
derived: sum of 2 quarters · filed 2022-11-08
$2.26M
10-Q · filed 2022-11-08
$1.80M
derived: sum of 4 quarters · filed 2022-11-08
2021-06-30-$356.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
$1.64M
10-Q · filed 2022-08-09
$1.18M
derived: sum of 3 quarters · filed 2022-08-09
$4.06M
derived: sum of 4 quarters · filed 2022-08-09
2021-03-31$1.99M
10-Q · filed 2022-05-11
$1.53M
derived: sum of 2 quarters · filed 2022-05-11
$4.42M
derived: sum of 3 quarters · filed 2022-05-11
$666.00K
derived: sum of 4 quarters · filed 2022-05-11
2020-12-31-$459.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17
$2.43M
derived: sum of 2 quarters · filed 2022-03-17
-$1.32M
derived: sum of 3 quarters · filed 2022-03-17
$1.07M
10-K · filed 2022-03-17
2020-09-30$2.89M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08
-$866.00K
derived: sum of 2 quarters · filed 2021-11-08
$1.53M
10-Q · filed 2021-11-08
$2.49M
derived: sum of 4 quarters · filed 2021-11-08
2020-06-30-$3.75M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12
-$1.36M
10-Q · filed 2021-08-12
-$401.00K
derived: sum of 3 quarters · filed 2021-08-12
-$175.00K
derived: sum of 4 quarters · filed 2021-08-12
2020-03-31$2.39M
10-Q · filed 2021-05-07
$3.35M
derived: sum of 2 quarters · filed 2021-05-07
$3.58M
derived: sum of 3 quarters · filed 2021-05-07
$3.90M
derived: sum of 4 quarters · filed 2021-05-07
2019-12-31$958.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25
$1.18M
derived: sum of 2 quarters · filed 2021-03-25
$1.51M
derived: sum of 3 quarters · filed 2021-03-25
$1.45M
10-K · filed 2021-03-25
2019-09-30$226.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10
$550.00K
derived: sum of 2 quarters · filed 2020-11-10
$496.00K
10-Q · filed 2020-11-10
2019-06-30$324.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11
$270.00K
10-Q · filed 2020-08-11
2019-03-31-$54.00K
10-Q · filed 2020-05-12
2018-12-31$264.00K
10-K · filed 2020-03-24

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cardiff Oncology, Inc. (CRDF)United States$0.101B-2.22
LENZ Therapeutics, Inc. (LENZ)United States$0.117B-1.41
COGNITION THERAPEUTICS INC (CGTX)United States$0.090B-6.52
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Pelthos Therapeutics Inc. (PTHS)United States$0.086B-1.20
Atara Biotherapeutics, Inc. (ATRA)United States$0.086B-6.48
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
Vaxart, Inc. (VXRT)United States$0.080B3.84